Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Br J Pharmacol. 2023 Dec;180(24):3215-3233. doi: 10.1111/bph.16200. Epub 2023 Aug 27.
Nonsteroidal anti-inflammatory drugs (NSAIDs) can be associated with severe adverse digestive effects. This study examined the protective effects of the probiotic Saccharomyces boulardii CNCM I-745 in a rat model of diclofenac-induced enteropathy.
Enteropathy was induced in 40-week-old male rats by intragastric diclofenac (4 mg·kg BID for 14 days). S. boulardii CNCM I-745 (3 g·kg BID by oral gavage) was administered starting 14 days before (preventive protocol) or along with (curative protocol) diclofenac administration. Ileal damage, inflammation, barrier integrity, gut microbiota composition and toll-like receptors (TLRs)-nuclear factor κB (NF-κB) pathway were evaluated.
Diclofenac elicited intestinal damage, along with increments of myeloperoxidase, malondialdehyde, tumour necrosis factor and interleukin-1β, overexpression of TLR2/4, myeloid differentiation primary response 88 (Myd88) and NF-κB p65, increased faecal calprotectin and butyrate levels, and decreased blood haemoglobin levels, occludin and butyrate transporter monocarboxylate transporter 1 (MCT1) expression. In addition, diclofenac provoked a shift of bacterial taxa in both faecal and ileal samples. Treatment with S. boulardii CNCM I-745, in both preventive and curative protocols, counteracted the majority of these deleterious changes. Only preventive administration of the probiotic counteracted NSAID-induced decreased expression of MCT1 and increase in faecal butyrate levels. Occludin expression, after probiotic treatment, did not significantly change.
Treatment with S. boulardii CNCM I-745 prevents diclofenac-induced enteropathy through anti-inflammatory and antioxidant activities. Such effects are likely to be related to increased tissue butyrate bioavailability, through an improvement of butyrate uptake by the enteric mucosa.
非甾体抗炎药(NSAIDs)可引起严重的不良消化道反应。本研究采用双氯芬酸钠诱导的大鼠肠病模型,探讨益生菌布拉氏酵母菌 CNCM I-745 的保护作用。
40 周龄雄性大鼠通过灌胃双氯芬酸钠(4mg·kg 每天两次,共 14 天)诱导肠病。双氯芬酸钠给药前 14 天(预防方案)或同时(治疗方案)开始口服布拉氏酵母菌 CNCM I-745(3g·kg 每天两次)。评估回肠损伤、炎症、屏障完整性、肠道微生物群组成和 toll 样受体(TLR)-核因子 κB(NF-κB)途径。
双氯芬酸钠引起肠道损伤,同时增加髓过氧化物酶、丙二醛、肿瘤坏死因子和白细胞介素-1β,TLR2/4、髓样分化初级反应 88(Myd88)和 NF-κB p65 过表达,粪便钙卫蛋白和丁酸盐水平升高,血液血红蛋白水平降低,occludin 和丁酸盐转运体单羧酸转运蛋白 1(MCT1)表达降低。此外,双氯芬酸钠引起粪便和回肠样本中细菌分类群的变化。在预防和治疗方案中,用布拉氏酵母菌 CNCM I-745 治疗可逆转大部分这些有害变化。只有预防性给予益生菌可逆转 NSAID 诱导的 MCT1 表达降低和粪便丁酸盐水平升高。益生菌治疗后,occludin 表达无明显变化。
用布拉氏酵母菌 CNCM I-745 治疗可通过抗炎和抗氧化作用预防双氯芬酸钠诱导的肠病。这些作用可能与通过改善肠黏膜摄取丁酸盐而增加组织丁酸盐生物利用度有关。